On December 23, 2014, the FDA approved liraglutide, under the name Saxenda, to treat obesity, after having previously approved it under the name Victoza to treat type 2 diabetes mellitus (T2DM). As ...

In a comparison of injectable GLP-1 receptor agonists, semaglutide (Wegovy) appeared to edge out liraglutide (Saxenda) when it came to weight loss, according to the phase IIIb STEP 8 study. In a ...

GLP-1 weight loss drugs such as Ozempic and Wegovy have taken the world by storm. But some side effects, from the accepted - ...

Liraglutide is an analog with 97% homology to human glucagon-like peptide (GLP-1) and acts as a GLP-1 receptor agonist. Several large, randomized, multicenter phase 3 trials evaluated the efficacy and ...

Study reveals liraglutide's potential to regulate iron metabolism and improve glucose tolerance in a mouse model of hereditary hemochromatosis and obesity. Study: Liraglutide Impacts Iron Homeostasis ...

New trial shows liraglutide helps reduce BMI in children aged 6 to 12 with obesity, but side effects prompt further study Study: Liraglutide for Children 6 to <12 Years of Age with Obesity — A ...

If you’re looking into weight loss drugs, liraglutide has no doubt popped up. It’s a diabetes and weight loss medication sold under the brand names Victoza and Saxenda. Read on for everything you need ...

Liraglutide (Saxenda) added to lifestyle intervention helped reduce BMI in young children with obesity, the phase IIIa SCALE Kids trial found. By week 56, kids, ages 6 to <12 years, on once-daily 3-mg ...

Fourteen years ago, the older drug cousin of semaglutide (Ozempic and Wegovy) came onto the market. The drug, liraglutide, is sold under the brand names Victoza and Saxenda. Patents for Victoza and ...

The GLP-1 agonist liraglutide (Victoza, Novo Nordisk) was the overall winner compared with three other diverse agents for treating patients with type 2 diabetes already maintained on metformin. But ...